Design of an epitope-based peptide vaccine against spike protein of human coronavirus: An in silico approach

Drug Design, Development and Therapy

Volumn 8, Issue , 2014, Pages 1139-1149

  Oany, Arafat Rahman ^a   Emran, Abdullah Al ^a,b   Jyoti, Tahmina Pervin ^c  

^a MAWLANA BHASHANI SCIENCE AND TECHNOLOGY UNIVERSITY   (Bangladesh)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c KHULNA UNIVERSITY   (Bangladesh)

Author keywords

Allergenicity; Atypical pneumonia; Docking; HLA; Vaccinomics

Indexed keywords

CORONA VIRUS VACCINE; EPITOPE; HLA A ANTIGEN; HLA A2 ANTIGEN; HLA A32 ANTIGEN; HLA A68 ANTIGEN; HLA ANTIGEN; HLA B ANTIGEN; HLA B15 ANTIGEN; HLA B27 ANTIGEN; HLA B40 ANTIGEN; HLA B58 ANTIGEN; HLA C ANTIGEN; HLA C12 ANTIGEN; HLA C3 ANTIGEN; PEPTIDE VACCINE; UNCLASSIFIED DRUG; VIRUS SPIKE PROTEIN; VIRUS VACCINE; CORONAVIRUS SPIKE GLYCOPROTEIN; SUBUNIT VACCINE;

ALLERGENICITY; AMINO ACID SEQUENCE; ANTIGEN BINDING; ARTICLE; CELLULAR IMMUNITY; CLIENT SERVER APPLICATION; COMPUTER MODEL; COMPUTER SYSTEM; CORONAVIRUS; DRUG DESIGN; DRUG TARGETING; HUMORAL IMMUNITY; IMMUNE RESPONSE; IN VITRO STUDY; IN VIVO STUDY; MOLECULAR DOCKING; PROTEIN INTERACTION; SEQUENCE ANALYSIS; SEQUENCE DATABASE; SUPPORT VECTOR MACHINE; COMPUTER SIMULATION; CORONAVIRIDAE; CORONAVIRUS INFECTIONS; HUMAN; IMMUNOLOGY; ISOLATION AND PURIFICATION; MOLECULAR GENETICS;

AMINO ACID SEQUENCE; COMPUTER SIMULATION; CORONAVIRUS; CORONAVIRUS INFECTIONS; EPITOPES, B-LYMPHOCYTE; EPITOPES, T-LYMPHOCYTE; HLA ANTIGENS; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; MOLECULAR DOCKING SIMULATION; MOLECULAR SEQUENCE DATA; SPIKE GLYCOPROTEIN, CORONAVIRUS; VACCINES, SUBUNIT; VIRAL VACCINES;

EID: 84906730613     PISSN: None     EISSN: 11778881     Source Type: Journal    
DOI: 10.2147/DDDT.S67861     Document Type: Article

References (61)

1. González JM, Gomez-Puertas P, Cavanagh D, Gorbalenya AE, Enjuanes L. A comparative sequence analysis to revise the current taxonomy of the family Coronaviridae. Arch Virol. 2003;148(11): 2207-2235.
2. Siddell SG. The Coronaviridae. New York, NY: Plenum Press; 1995.
3. Drexler JF, Gloza-Rausch F, Glende J, et al. Genomic characterization of severe acute respiratory syndrome-related coronavirus in European bats and classification of coronaviruses based on partial RNA-dependent RNA polymerase gene sequences. J Virol. 2010;84(21):11336-11349.
4. Cavanagh D, Mawditt K, Welchman Dde B, Britton P, Gough RE. Coronaviruses from pheasants (Phasianus colchicus) are genetically closely related to coronaviruses of domestic fowl (infectious bronchitis virus) and turkeys. Avian Pathol. 2002;31(1):81-93.
5. Parry J. WHO investigates China's fall in SARS cases. BMJ. 2003; 326(7402):1285.
6. Yoo D, Deregt D. A single amino acid change within antigenic domain II of the spike protein of bovine coronavirus confers resistance to virus neutralization. Clin Diagn Lab Immunol. 2001;8(2):297-302.
7. Poland GA, Ovsyannikova IG, Jacobson RM. Application of pharmacogenomics to vaccines. Pharmacogenomics. 2009;10(5):837-852.
8. Flower DR. Bioinformatics for Vaccinology. Chichester: John Wiley & Sons, Ltd; 2008.
9. Bourdette DN, Edmonds E, Smith C, et al. A highly immunogenic trivalent T cell receptor peptide vaccine for multiple sclerosis. Mult Scler. 2005;11(5):552-561.
10. López JA, Weilenman C, Audran R, et al. A synthetic malaria vaccine elicits a potent CD8(+) and CD4(+) T lymphocyte immune response in humans. Implications for vaccination strategies. Eur J Immunol. 2001;31(7):1989-1998.
11. Knutson KL, Schiffman K, Disis ML. Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients. J Clin Invest. 2001;107(4):477-484.
12. Petrovsky N, Brusic V. Computational immunology: The coming of age. Immunol Cell Biol. 2002;80(3):248-254.
13. Brusic V, Bajic VB, Petrovsky N. Computational methods for prediction of T-cell epitopes-a framework for modelling, testing, and applications. Methods. 2004;34(4):436-443.
14. Peters B, Bulik S, Tampe R, Van Endert PM, Holzhütter HG. Identifying MHC class I epitopes by predicting the TAP transport efficiency of epitope precursors. J Immunol. 2003;171(4):1741-1749.
15. Bhasin M, Raghava GP. Analysis and prediction of affinity of TAP binding peptides using cascade SVM. Protein Sci. 2004;13(3): 596-607.
16. Nielsen M, Lundegaard C, Lund O, Keşmir C. The role of the proteasome in generating cytotoxic T-cell epitopes: insights obtained from improved predictions of proteasomal cleavage. Immunogenetics. 2005;57(1-2):33-41.
17. Apweiler R, Bairoch A, Wu CH, et al. UniProt: the universal protein knowledgebase. Nucleic Acids Res. 2004;32(Suppl 1):D115-D119.
18. Larkin MA, Blackshields G, Brown NP, et al. Clustal W and Clustal X version 2.0. Bioinformatics. 2007;23(21):2947-2948.
19. Doytchinova IA, Flower DR. VaxiJen: a server for prediction of protective antigens, tumour antigens and subunit vaccines. BMC Bioinformatics. 2007;8:4.
20. Larsen MV, Lundegaard C, Lamberth K, Buus S, Lund O, Nielsen M. Large-scale validation of methods for cytotoxic T-lymphocyte epitope prediction. BMC Bioinformatics. 2007;8:424.
21. Buus S, Lauemøller SL, Worning P, et al. Sensitive quantitative predictions of peptide-MHC binding by a 'Query by Committee' artificial neural network approach. Tissue Antigens. 2003;62(5): 378-384.
22. Peters B, Sette A. Generating quantitative models describing the sequence specificity of biological processes with the stabilized matrix method. BMC Bioinformatics. 2005;6:132.
23. Tenzer S, Peters B, Bulik S, et al. Modeling the MHC class I pathway by combining predictions of proteasomal cleavage, TAP transport and MHC class I binding. Cell Mol Life Sci. 2005; 62:1025-1037.
24. Bui HH, Sidney J, Li W, Fusseder N, Sette A. Development of an epitope conservancy analysis tool to facilitate the design of epitope-based diagnostics and vaccines. BMC Bioinformatics. 2007; 8(1):361.
25. Muh HC, Tong JC, Tammi MT. AllerHunter: a SVM-pairwise system for assessment of allergenicity and allergic cross-reactivity in proteins. PLoS One. 2009;4(6):e5861.
26. Liao L, Noble WS. Combining pairwise sequence similarity and support vector machines for detecting remote protein evolutionary and structural relationships. J Comput Biol. 2003;10(6):857-868.
27. Chen YPP, Wong L, editors. A Better Gap Penalty for Pairwise-SVM: Proceedings of the 3rd Asia-Pacific Bioinformatics, Singapore, January 17-21, 2005. Singapore: Scientific Publishing Co; 2005.
28. Thévenet P, Shen Y, Maupetit J, Guyon F, Derreumaux P, Tufféry P. PEP-FOLD: an updated de novo structure prediction server for both linear and disulfide bonded cyclic peptides. Nucleic Acids Res. 2012;40(Web Server issue):W288-W293.
29. Thomsen R, Christensen MH. MolDock: a new technique for high-accuracy molecular docking. J Med Chem. 2006;49(11):3315-3321.
30. Berman HM, Westbrook J, Feng Z, et al. The protein data bank. Nucleic Acids Res. 2000;28(1):235-242.
31. Nair DT, Singh K, Siddiqui Z, Nayak BP, Rao KV, Salunke DM. Epitope recognition by diverse antibodies suggests conformational convergence in an antibody response. J Immunol. 2002;168(5):2371-2382.
32. Kolaskar AS, Tongaonkar PC. A semi-empirical method for prediction of antigenic determinants on protein antigens. FEBS Lett. 1990;276(1-2):172-174.
33. Emini EA, Hughes JV, Perlow DS, Boger J. Induction of hepatitis A virus-neutralizing antibody by a virus-specific synthetic peptide. J Virol. 1985;55(3):836-839.
34. Karplus PA, Schulz GE. Prediction of chain flexibility in proteins. Naturwissenschaften. 1985;72(4):212-213.
35. Larsen JE, Lund O, Nielsen M. Improved method for predicting linear B-cell epitopes. Immunome Res. 2006;2(1):2.
36. Chou PY, Fasman GD. Empirical predictions of protein conformation. Annu Rev Biochem. 1978;47:251-276.
37. Rini JM, Schulze-Gahmen U, Wilson IA. Structural evidence for induced fit as a mechanism for antibody-antigen recognition. Science. 1992;255(5047):959-965.
38. Rose GD, Gierasch L, Smith JA. Turns in peptides and proteins. Adv Protein Chem. 1985;37:1-109.
39. Novotný J, Handschumacher M, Haber E, et al. Antigenic determinants in proteins coincide with surface regions accessible to large probes (antibody domains). Proc Natl Acad Sci U S A. 1986;83(2):226-230.
40. Marshall SJ. Developing countries face double burden of disease. Bull World Health Organ. 2004;82(7):556.
41. De Groot AS, Rappuoli R. Genome-derived vaccines. Expert Rev Vaccines. 2004;3(1):59-76.
42. Korber B, LaBute M, Yusim K. Immunoinformatics comes of age. PLoS Comput Biol. 2006;2(6):e71.
43. Fauci AS. Emerging and re-emerging infectious diseases: influenza as a prototype of the host-pathogen balancing act. Cell. 2006;124(4): 665-670.
44. Purcell AW, McCluskey J, Rossjohn J. More than one reason to rethink the use of peptides in vaccine design. Nat Rev Drug Discov. 2007;6(5): 404-414.
45. Lapelosa M, Gallicchio E, Arnold GF, Arnold E, Levy RM. In silico vaccine design based on molecular simulations of rhinovirus chimeras presenting HIV-1 gp41 epitopes. J Mol Biol. 2009;385(2):675-691.
46. Chakraborty S, Chakravorty R, Ahmed M, et al. A computational approach for identification of epitopes in dengue virus envelope protein: a step towards designing a universal dengue vaccine targeting endemic regions. In Silico Biol. 2010;10(5-6):235-246.
47. Islam R, Sakib MS, Zaman A. A computational assay to design an epitope-based peptide vaccine against chikungunya virus. Future Virol. 2012;7(10):1029-1042.
48. Hasan MA, Hossain M, Alam MJ. A computational assay to design an epitope-based Peptide vaccine against Saint Louis encephalitis virus. Bioinform Biol Insights. 2013;7:347-355.
49. Twiddy SS, Holmes EC, Rambaut A. Inferring the rate and time-scale of dengue virus evolution. Mol Biol Evol. 2003;20(1):122-129.
50. Manzin A, Solforosi L, Petrelli E, et al. Evolution of hypervariable region 1 of hepatitis C virus in primary infection. J Virol. 1998;72(7): 6271-6276.
51. Christie JM, Chapel H, Chapman RW, Rosenberg WM. Immune selection and genetic sequence variation in core and envelope regions of hepatitis C virus. Hepatology. 1999;30(4):1037-1044.
52. Ma C, Li Y, Wang L, et al. Intranasal vaccination with recombinant receptor-binding domain of MERS-CoV spike protein induces much stronger local mucosal immune responses than subcutaneous immunization: Implication for designing novel mucosal MERS vaccines. Vaccine. 2014;32(18):2100-2108.
53. Yang ZY, Kong WP, Huang Y, et al. A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice. Nature. 2004;428(6982):561-564.
54. Agnihothram S, Gopal R, Yount BL, et al. Platform strategies for rapid response against emerging coronaviruses: MERS-CoV serologic and antigenic relationships in vaccine design. J Infect Dis [serial on the Internet]. Nov 2013 [cited May 16, 2014]. Available from: http://jid.oxfordjournals.org/content/early/2013/11/18/infdis.jit609. Accessed July 12, 2014.
55. Shrestha B, Diamond MS. Role of CD8+ T cells in control of West Nile virus infection. J Virol. 2004;78(15):8312-8321.
56. Sharmin R, Islam AB. A highly conserved WDYPKCDRA epitope in the RNA directed RNA polymerase of human coronaviruses can be used as epitope-based universal vaccine design. BMC Bioinformatics. 2014;15:161.
57. van der Hoek L, Pyrc K, Jebbink MF, et al. Identification of a new human coronavirus. Nat Med. 2004;10(4):368-373.
58. Hofmann H, Pyrc K, van der Hoek L, Geier M, Berkhout B, Pöhlmann S. Human coronavirus NL63 employs the severe acute respiratory syndrome coronavirus receptor for cellular entry. Proc Natl Acad Sci U S A. 2005;102(22):7988-7993.
59. Chiu SS, Chan KH, Chu KW, et al. Human coronavirus NL63 infection and other coronavirus infections in children hospitalized with acute respiratory disease in Hong Kong, China. Clin Infect Dis. 2005;40(12):1721-1729.
60. McKeever TM, Lewis SA, Smith C, Hubbard R. Vaccination and allergic disease: a birth cohort study. Am J Public Health. 2004;94(6): 985-989.
61. Khan MK, Zaman S, Chakraborty S, et al. In silico predicted mycobacterial epitope elicits in vitro T-cell responses. Mol Immunol. 2014;61(1):16-22.